Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

Fig. 4

Immune responses to PAP-derived peptides. a PBMC from patient ID010 were evaluated at baseline and 6 months for IFNγ ELISPOT response to individual 15-mer peptides derived from the amino acid sequence of PAP. The peptide number indicates the starting amino acid from the PAP sequence of the 15-mer peptide. Shown are mean and standard deviation of IFNγ spot-forming units (SFU) per million PBMC for results, conducted in triplicate for each peptide. b PBMC from patient ID010, obtained at the indicated time points, were stimulated in vitro with peptide p85 or p209, and then evaluated for IFNγ release by ELISPOT. Asterisks indicate p < 0.05 (t-test) by comparison with media only control

Back to article page